Description

IVERHEAL 12 MG

Indications

IVERHEAL 12 MG is primarily indicated for the treatment of various parasitic infections, including strongyloidiasis and onchocerciasis. It is also utilized in the management of certain viral infections, particularly those caused by the SARS-CoV-2 virus, as part of an off-label treatment regimen. IVERHEAL contains Ivermectin as its active ingredient, which has proven efficacy against a range of parasites and some viral pathogens.

Mechanism of Action

The active component of IVERHEAL, Ivermectin, exerts its pharmacological effects through the binding to specific channels in the nerve and muscle cells of parasites. It enhances the release of gamma-aminobutyric acid (GABA), leading to paralysis and death of the parasites. Additionally, Ivermectin disrupts the function of glutamate-gated chloride channels, which are crucial for the survival of various nematodes and arthropods. This dual action makes IVERHEAL effective in treating infections caused by these organisms.

Pharmacological Properties

IVERHEAL 12 MG is characterized by its broad-spectrum antiparasitic activity. It is well-absorbed in the gastrointestinal tract, with peak plasma concentrations typically occurring within 4 hours post-administration. The drug is metabolized in the liver, primarily through the cytochrome P450 enzyme system, and has a half-life of approximately 18 hours. Ivermectin is excreted mainly in the feces, with minimal renal excretion. The pharmacokinetics of IVERHEAL may vary based on the individual’s age, weight, and liver function.

Contraindications

IVERHEAL 12 MG is contraindicated in individuals with a known hypersensitivity to Ivermectin or any of its components. It should not be used in patients with severe liver impairment or those with a history of neurological disorders, such as meningitis or encephalopathy. Furthermore, the use of IVERHEAL is not recommended in pregnant or breastfeeding women due to potential risks to the fetus or infant.

Side Effects

Common side effects associated with IVERHEAL 12 MG include dizziness, nausea, diarrhea, and fatigue. Some patients may experience skin rashes or itching. Serious side effects, although rare, can occur and may include hypotension, seizures, and severe allergic reactions such as anaphylaxis. Patients should be monitored for any adverse effects, especially after the first dose, and medical attention should be sought if severe reactions occur.

Dosage and Administration

The recommended dosage of IVERHEAL 12 MG varies depending on the specific indication and the patient’s body weight. For the treatment of strongyloidiasis, the typical dosage is a single oral dose of 200 mcg/kg. For onchocerciasis, the dosage may be repeated every 6 to 12 months based on the severity of the infection. It is essential to follow healthcare provider instructions regarding the appropriate dosage and duration of therapy. IVERHEAL should be taken with water on an empty stomach to enhance absorption.

Interactions

IVERHEAL 12 MG may interact with other medications, potentially altering their effects. Notably, the concomitant use of Ivermectin with certain drugs that affect the cytochrome P450 enzyme system may lead to increased plasma concentrations of Ivermectin, heightening the risk of side effects. Medications such as anticonvulsants and certain antibiotics should be used cautiously in patients receiving IVERHEAL. It is crucial for patients to inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Before initiating treatment with IVERHEAL 12 MG, a thorough medical history and physical examination should be conducted. Patients with a history of liver disease, neurological disorders, or those who are immunocompromised should be closely monitored during therapy. Additionally, patients should be advised to avoid driving or operating heavy machinery until they know how IVERHEAL affects them, as dizziness may occur. Regular follow-up appointments are recommended to assess treatment efficacy and monitor for any adverse effects.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of IVERHEAL 12 MG in treating parasitic infections. A randomized controlled trial published in the Journal of Infectious Diseases showed that Ivermectin significantly reduced the burden of strongyloidiasis in treated patients compared to a placebo group. Another study published in the American Journal of Tropical Medicine and Hygiene highlighted the effectiveness of Ivermectin in reducing the prevalence of onchocerciasis in endemic regions. These studies support the use of IVERHEAL as a safe and effective treatment option for specific parasitic infections.

Conclusion

IVERHEAL 12 MG is a valuable therapeutic agent in the management of various parasitic infections and certain viral conditions. Its mechanism of action, pharmacological properties, and clinical efficacy make it an essential tool in infectious disease treatment. However, careful consideration of contraindications, potential side effects, and drug interactions is necessary to ensure patient safety and optimal therapeutic outcomes. Patients should always consult their healthcare provider before starting treatment with IVERHEAL and adhere to prescribed dosages for effective management of their conditions.